Tablet screening app can improve eye health outcomes in remote, underserved communities

Nepal study shows tablet-based test could lead to earlier intervention and improved eye health outcomes in low-resource communities

Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. In this study, researchers from the University of Iowa, the University of Maryland, Johns Hopkins University, the University of Michigan and the Tilganga Eye Institute in Nepal used a free peripheral vision assessment app to screen approximately 200 patients in Nepal for glaucoma using an iPad®. The results show promise for screening populations that have limited or no access to traditional eye care and certain ethnic groups that have a high risk of developing the disease.

Glaucoma is the second leading cause of blindness worldwide, affecting more than 60.5 million people. The disease can be effectively treated; however, it generally does not present symptoms in its early stages, resulting in many patients being unaware that they suffer from the condition until it progresses to later stages. Early diagnosis can easily be achieved through a routine examination from an ophthalmologist – a medical doctor specializing in the diagnosis, medical and surgical treatment of eye diseases and conditions – or an optometrist. While it is relatively easy for patients with access to regular health care in developed nations to be screened for glaucoma during a routine eye examination, remote and underserved communities have limited or no access to such services, increasing their risk for glaucoma-related blindness.

In order to determine if a screening test using mobile technology could be effectively administered to communities outside of a traditional clinical setting, the research team used the Visual Fields Easy app, which simulates a visual field test on an iPad (1st Generation), to screen more than 400 eyes for glaucoma.

Approximately half of the eyes screened were healthy "control" eyes and the other half were eyes with glaucoma. The researchers compared the screening results to those from the traditional industry standard visual field test, known as the Humphrey SITA Standard 24-2, and found that the two tests agreed between 51-79 percent of the time.

The best agreement was in patients with moderate and advanced visual field loss, while there was less agreement in patients with mild visual field loss. The researchers believe this was due to a high false positive rate for normal controls. While the agreement rate and cost-benefit ratio of the results were not strong enough to support using the method for screening general populations, the researchers believe that conducting screenings using a tablet can be an effective initial screening tool for high-risk groups, such as people of African or Hispanic ancestry, the elderly and people with limited or no access to traditional eye and health care. In addition, the screenings lasted an average of 3 minutes and 18 seconds – less than half the average time needed for the Humphrey SITA Standard test.

"Visual field testing equipment is neither portable nor affordable to some populations around the world, limiting entire regions from accessing health and eye care," said lead researcher Chris A. Johnson, Ph.D., director of the Visual Field Reading Center at the University of Iowa. "Although not perfect, the tablet glaucoma screening method could make a significant difference in remote locations where populations would not otherwise receive screening at all."

Use of an iPad to Perform Visual Field Screening in Nepal (PO412) is being presented today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology which is in session October 17-21 at McCormick Place in Chicago. More than 25,000 attendees and 620 companies from 123 countries gather each year to showcase the latest in ophthalmic education, research and technology. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel gene responsible for some inherited retinal diseases identified